Latest It Compliance News

Acorn Capital Investment Fund Limited has been suspended from ASX trading due to a delayed periodic report, raising questions about its compliance and investor transparency.

Neurizon Therapeutics received FDA guidance on its IND application for NUZ-001, with a single request for additional animal exposure data but no safety concerns flagged. The company is actively addressing the FDA’s request while evaluating impacts on its ALS trial timeline.

Bendigo and Adelaide Bank has released its Basel III Pillar 3 disclosures for the year ended December 31, 2024, revealing solid capital adequacy and liquidity positions under APRA regulations. The bank maintains robust buffers amid lending growth and evolving market conditions.

GPT Group has confirmed a fully unfranked ordinary dividend of AUD 0.12 per security for the six months ending December 2024, payable on February 28, 2025.

Bendigo and Adelaide Bank has announced a fully franked ordinary dividend of AUD 0.30 per share for the half-year ending December 2024, reinforcing its steady shareholder returns.

Bendigo and Adelaide Bank reported a modest dip in cash earnings for the half year ended December 2024, offset by strong residential lending growth and a maintained fully franked dividend. The bank’s strategic investments and digital transformation efforts continue amid margin compression and rising expenses.

The Calmer Co. International Limited has secured a $2.64 million FJD loan from Fiji Development Bank to acquire a key Navua facility, marking a strategic step to bolster its kava processing and staff infrastructure.

Carly Holdings Limited has agreed to merge its car subscription operations with Carbar Holdings in a $3.8 million deal, aiming to create a larger, more competitive player in Australia’s growing car subscription sector.

Many Peaks Minerals Limited has amended its previous ASX announcement on auger sampling at the Ferké Gold Project to enhance regulatory compliance, while continuing to advance exploration with diamond drilling and planned air core and RC programs.

Avecho Biotechnology has responded to an ASX price query, confirming no undisclosed information exists to explain recent trading spikes, while highlighting market speculation linked to its Phase III CBD insomnia trial.

Laramide Resources Ltd. has acknowledged a delayed filing of a director's interest notice due to internal illness, prompting an ASX inquiry and procedural upgrades to prevent future lapses.

Scorpion Minerals Limited has had its trading suspension lifted following an announcement about a potential joint venture and capital raising, signaling renewed market activity.